Targeted Delivery of Iomab-B to the Marrow in Patients with R/R AML
Rajneesh Nath, MD, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia population.
Rajneesh Nath, MD, a medical oncologist with Banner Health, discusses his hypothesis on the benefits of targeted delivery of Iomab-B to the marrow in the older relapsed or refractory acute myeloid leukemia (AML) population. His findings were presented at the 2021 Transplantation & Cellular Therapy Meetings.
According to Nath, the 2 most common types of stem cell transplantation are myeloablation and reduced intensity. Myeloablation is associated with increased intensity of chemotherapy and higher doses of radiation. This tends to increase the toxicity of treatment for the patient.
Nath’s hypothesis that delivery of Iomab-B directly to where it is needed can help reduce toxicity and save critical organs such as the heart, lungs and kidney. The study found that Iomab-B was able to spare the gastrointestinal tract. According to Nath, instances of sepsis in the Iomab-B group was 4% while in the standard of care group, it was 13%.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
